Clinical trial Recruiting at 1 site Observational Ages 20 and up

Evaluating the Prognostic Value of Hemodynamic Indices in Coronary Artery Disease

Official title: Prognostic Impact of Lesion-specific Hemodynamic Index and Disease Characteristics in Patients With Coronary Artery Disease Assessed by Fractional Flow Reserve

Run by Seoul National University Hospital · NCT05250557 · Data updated 2026-11-12

This study is testing if certain blood flow measurements can help predict how well patients with coronary artery disease will do after a heart procedure.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages20 Years and up
SexAll
Enrollment2429 (estimated)
SponsorSeoul National University Hospital
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedAugust 1, 2021
Main results expectedDecember 31, 2025
Study endsDecember 31, 2026
Registry record updatedFebruary 22, 2022
Trial IDNCT05250557 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 20 years and older who have undergone successful FFR measurement.

Probably not a fit

Patients with chronic renal failure, recent ST-elevation myocardial infarction, or significant heart conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the prognostic value of lesion-specific hemodynamic indices, such as ΔFFR and RFR, in patients with coronary artery disease. It aims to assess how these indices, alongside traditional measures like % diameter stenosis and FFR, can improve risk prediction for patients undergoing percutaneous coronary intervention (PCI). The study will also explore the implications of post-PCI FFR in conjunction with various clinical and disease characteristics to develop a comprehensive risk prediction model. By doing so, it seeks to enhance the understanding of local hemodynamics in predicting patient outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved risk stratification and treatment outcomes for patients with coronary artery disease undergoing PCI.

How similar studies have gone: While the use of FFR in clinical practice is established, this specific approach to evaluating ΔFFR and RFR in a prospective manner is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥20 years
2. All comers who underwent successful FFR measurement and pullback tracing

Exclusion Criteria:

1. Chronic renal failure (estimated glomerular filtration rate \<30)
2. ST-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery history
3. Primary myocardial or valvular disease
4. Left ventricular ejection fraction \< 30%
5. Hemodynamically unstable clinical conditions
6. Life expectancy \< 2 years

Where it's running

  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting

Study contacts

  • Principal investigator: Bon-Kwon Koo, MD, PhD — Seoul National University Hospital
  • Study coordinator: Bon-Kwon Koo, MD, PhD
  • Email: bkkoo@snu.ac.kr
  • Phone: +82-2-2072-2062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.